Hiroshi Uchiya

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-β injections was formulated according to the types of resistance-associated substitutions (RAS) in the non-structural protein (NS)5A region of(More)
  • 1